Chewy earnings analysis: questions answered and next catalysts

Chewy reported Q2 revenue of $3.33B (+7.3% YoY), adjusted EBITDA margin of 6.8%, and adjusted EPS of $0.36 in line with consensus, but shares fell 10.16% to $20.91 as investors questioned the durability of margin gains. Autoship sales rose 9.3% to $2.8B, representing 84.6% of revenue, while active customers increased 3.8% to 21.7M and the company repurchased $200M of stock. Q3 guidance calls for $3.323B-$3.358B in revenue and 6.6%-6.7% EBITDA margin; full-year margin guidance was raised to 6.7%-6.8%, though timing-related Q2 gross-margin benefits remain a key investor concern.

Analysis

The selloff creates a useful distinction between a one-quarter margin print and a rerating case. At roughly $21, CHWY is being priced as though customer growth remains structurally low-single-digit and incremental margin will be competed away; that is plausible, but the stock’s downside should increasingly be supported by recurring revenue, buybacks, and a less promotional cost base. The near-term issue is not EPS but whether gross-margin normalization offsets operating leverage—an outcome that determines whether the market assigns a retail multiple or a higher-quality subscription-like multiple.

The non-obvious risk is that health-services expansion can dilute the core model before it improves lifetime value. Veterinary clinics and care delivery introduce fixed labor, local-density, and execution risk that Autoship does not carry; weak clinic contribution margins could consume the SG&A savings underpinning the current earnings story. Conversely, evidence that health offerings reduce churn or lower customer-acquisition costs would make the existing customer base materially more valuable than the market currently credits.

Into the next report, the cleanest catalyst is durable EBITDA margin at or above management’s implied run-rate alongside continued net customer additions. A miss driven by margin reversal—not merely modest revenue softness—would likely trigger another leg down because it would validate the market’s quality-of-earnings concern. APP and SMCI have no fundamental read-through from this event; their inclusion is article-template noise and should not drive positioning.

Key Decisions for Investors

• Watch, do not chase CHWY immediately: initiate a starter long only if shares stabilize above $20 and interim evidence supports gross-margin durability; add after Q3 if EBITDA margin is at least 6.6% and net customer additions remain above 200,000. Upside is a multiple rerating toward the low-$30s over 6-12 months; thesis fails on sub-6.4% EBITDA margin or renewed customer attrition.
• For event risk, express bullish exposure with a defined-risk CHWY Dec-2026 call spread rather than common stock ahead of earnings—for example, buy the $22.50 call/sell the $30 call if premium is no more than roughly one-third of spread width. This targets confirmation-driven rerating while limiting loss if margin timing reverses.
• Avoid using CHWY as a broad consumer discretionary proxy over the next 1-3 months. The relevant driver is cohort retention, fulfillment productivity, and healthcare-unit economics, not a generic retail-demand recovery; require disclosure on Modern Animal contribution margin and customer-acquisition cost before underwriting health-services upside.
• Set a downside alert at $18: a break below that level without a broad market selloff would signal that investors are discounting a more permanent margin reset. In that case, defer long exposure until management quantifies timing-related gross-margin benefits and clinic investment requirements.